Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NNC0662-0419 · NNC0662

Other · developed by Novo Nordisk

Phase 1 Most advanced trial
NVO Developer

What is NNC0662-0419?

NNC0662-0419 is a once-weekly subcutaneous agent given by pen injector. It is studied in overweight and obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NNC0662
Drug type
Other
Therapy area
Metabolic
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

ObesityOverweight

More from Novo Nordisk

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind NNC0662-0419

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.